Impact of the COVID-19 pandemic on inflammatory bowel disease care in Taiwan: A multicenter study

Yen Ling Peng; Chung Hsin Chang; Shu Chen Wei; Tien Yu Huang; Wei Chen Tai; Wen Hung Hsu; Deng Chyang Wu; Hsu Heng Yen; Chi Ming Tai; Chen Wang Chang; Wei Chen Lin; Horng Yuan Wang; Chun Chi Lin; Chia Jung Kuo; Cheng Tang Chiu; Ching Pin Lin; Hsi Chang Lee; Jia Feng Wu; Chen Shuan Chung

doi:10.1016/j.jfma.2023.03.017

Impact of the COVID-19 pandemic on inflammatory bowel disease care in Taiwan: A multicenter study

Yen Ling Peng, Chung Hsin Chang, Shu Chen Wei, Tien Yu Huang, Wei Chen Tai, Wen Hung Hsu, Deng Chyang Wu, Hsu Heng Yen, Chi Ming Tai, Chen Wang Chang, Wei Chen Lin, Horng Yuan Wang, Chun Chi Lin, Chia Jung Kuo, Cheng Tang Chiu, Ching Pin Lin, Hsi Chang Lee, Jia Feng Wu, Chen Shuan Chung^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal Article › peer-review

2 Scopus citations

Abstract

BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic had a great impact on healthcare system and patients. This study aimed to evaluate the effect of the COVID-19 pandemic on the perceptions of patients with inflammatory bowel disease (IBD).

METHODS: This prospective multicenter study was conducted between July 2021 and December 2021. Patients with IBD answered a structured questionnaire, and their degree of anxiety was assessed using a visual analogue scale (VAS) before and after reading educational materials.

RESULTS: A total of 225 (47.67%) patients with Crohn's disease, 244 (51.69%) with ulcerative colitis and 3 (0.64%) with indeterminate colitis were enrolled. Common concerns were adverse events from vaccination (20.34%), and higher risks of developing severe COVID-19 (19.28%) and COVID-19 infection (16.31%) than the general population. Medications deemed by the patients to increase the risk of COVID-19 were immunomodulators (16.10%), anti-tumor necrosis factor-α antagonists (9.96%), and corticosteroids (9.32%). Thirty-five (7.42%) patients self-discontinued IBD medication, of whom 12 (34.28%) had worse symptoms. Older age (>50 years) (OR 1.10, 95% CI 1.01-1.19, p = 0.03), IBD-related complications (OR 1.16, 95% CI 1.04-1.28, p = 0.01), education status below senior high school (OR 1.22, 95% CI 1.08-1.37, p = 0.001), and residing in north-central Taiwan (OR 1.21, 95% CI 1.10-1.34, p < 0.001) were associated with more anxiety. None of the enrolled patients contracted COVID-19. The anxiety VAS score (mean ± SD) improved after reading the educational materials (3.84 ± 2.33 vs. 2.81 ± 1.96, p < 0.001).

CONCLUSION: The medical behavior of IBD patients was influenced by the COVID-19 pandemic, and their anxiety could be mitigated after education.

Original language	English
Pages (from-to)	1042-1049
Number of pages	8
Journal	Journal of the Formosan Medical Association
Volume	122
Issue number	10
DOIs	https://doi.org/10.1016/j.jfma.2023.03.017
State	Published - 10 2023
Externally published	Yes

Bibliographical note

Keywords

COVID-19
Inflammatory bowel disease
Patient education
SARS-CoV-2
Inflammatory Bowel Diseases/complications
COVID-19/epidemiology
Pandemics
Prospective Studies
Humans
Taiwan/epidemiology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jfma.2023.03.017

Cite this

Peng, Y. L., Chang, C. H., Wei, S. C., Huang, T. Y., Tai, W. C., Hsu, W. H., Wu, D. C., Yen, H. H., Tai, C. M., Chang, C. W., Lin, W. C., Wang, H. Y., Lin, C. C., Kuo, C. J., Chiu, C. T., Lin, C. P., Lee, H. C., Wu, J. F., & Chung, C. S. (2023). Impact of the COVID-19 pandemic on inflammatory bowel disease care in Taiwan: A multicenter study. Journal of the Formosan Medical Association, 122(10), 1042-1049. https://doi.org/10.1016/j.jfma.2023.03.017

@article{decc18f287344540abdf8fcd27dcf0e6,

title = "Impact of the COVID-19 pandemic on inflammatory bowel disease care in Taiwan: A multicenter study",

abstract = "BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic had a great impact on healthcare system and patients. This study aimed to evaluate the effect of the COVID-19 pandemic on the perceptions of patients with inflammatory bowel disease (IBD).METHODS: This prospective multicenter study was conducted between July 2021 and December 2021. Patients with IBD answered a structured questionnaire, and their degree of anxiety was assessed using a visual analogue scale (VAS) before and after reading educational materials.RESULTS: A total of 225 (47.67%) patients with Crohn's disease, 244 (51.69%) with ulcerative colitis and 3 (0.64%) with indeterminate colitis were enrolled. Common concerns were adverse events from vaccination (20.34%), and higher risks of developing severe COVID-19 (19.28%) and COVID-19 infection (16.31%) than the general population. Medications deemed by the patients to increase the risk of COVID-19 were immunomodulators (16.10%), anti-tumor necrosis factor-α antagonists (9.96%), and corticosteroids (9.32%). Thirty-five (7.42%) patients self-discontinued IBD medication, of whom 12 (34.28%) had worse symptoms. Older age (>50 years) (OR 1.10, 95% CI 1.01-1.19, p = 0.03), IBD-related complications (OR 1.16, 95% CI 1.04-1.28, p = 0.01), education status below senior high school (OR 1.22, 95% CI 1.08-1.37, p = 0.001), and residing in north-central Taiwan (OR 1.21, 95% CI 1.10-1.34, p < 0.001) were associated with more anxiety. None of the enrolled patients contracted COVID-19. The anxiety VAS score (mean ± SD) improved after reading the educational materials (3.84 ± 2.33 vs. 2.81 ± 1.96, p < 0.001).CONCLUSION: The medical behavior of IBD patients was influenced by the COVID-19 pandemic, and their anxiety could be mitigated after education.",

keywords = "COVID-19, Inflammatory bowel disease, Patient education, SARS-CoV-2, Inflammatory Bowel Diseases/complications, COVID-19/epidemiology, Pandemics, Prospective Studies, Humans, Taiwan/epidemiology",

author = "Peng, {Yen Ling} and Chang, {Chung Hsin} and Wei, {Shu Chen} and Huang, {Tien Yu} and Tai, {Wei Chen} and Hsu, {Wen Hung} and Wu, {Deng Chyang} and Yen, {Hsu Heng} and Tai, {Chi Ming} and Chang, {Chen Wang} and Lin, {Wei Chen} and Wang, {Horng Yuan} and Lin, {Chun Chi} and Kuo, {Chia Jung} and Chiu, {Cheng Tang} and Lin, {Ching Pin} and Lee, {Hsi Chang} and Wu, {Jia Feng} and Chung, {Chen Shuan}",

year = "2023",

month = oct,

doi = "10.1016/j.jfma.2023.03.017",

language = "英语",

volume = "122",

pages = "1042--1049",

journal = "Journal of the Formosan Medical Association",

issn = "0929-6646",

publisher = "Elsevier B.V.",

number = "10",

}

Peng, YL, Chang, CH, Wei, SC, Huang, TY, Tai, WC, Hsu, WH, Wu, DC, Yen, HH, Tai, CM, Chang, CW, Lin, WC, Wang, HY, Lin, CC, Kuo, CJ, Chiu, CT, Lin, CP, Lee, HC, Wu, JF & Chung, CS 2023, 'Impact of the COVID-19 pandemic on inflammatory bowel disease care in Taiwan: A multicenter study', Journal of the Formosan Medical Association, vol. 122, no. 10, pp. 1042-1049. https://doi.org/10.1016/j.jfma.2023.03.017

TY - JOUR

T1 - Impact of the COVID-19 pandemic on inflammatory bowel disease care in Taiwan

T2 - A multicenter study

AU - Peng, Yen Ling

AU - Chang, Chung Hsin

AU - Wei, Shu Chen

AU - Huang, Tien Yu

AU - Tai, Wei Chen

AU - Hsu, Wen Hung

AU - Wu, Deng Chyang

AU - Yen, Hsu Heng

AU - Tai, Chi Ming

AU - Chang, Chen Wang

AU - Lin, Wei Chen

AU - Wang, Horng Yuan

AU - Lin, Chun Chi

AU - Kuo, Chia Jung

AU - Chiu, Cheng Tang

AU - Lin, Ching Pin

AU - Lee, Hsi Chang

AU - Wu, Jia Feng

AU - Chung, Chen Shuan

PY - 2023/10

Y1 - 2023/10

N2 - BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic had a great impact on healthcare system and patients. This study aimed to evaluate the effect of the COVID-19 pandemic on the perceptions of patients with inflammatory bowel disease (IBD).METHODS: This prospective multicenter study was conducted between July 2021 and December 2021. Patients with IBD answered a structured questionnaire, and their degree of anxiety was assessed using a visual analogue scale (VAS) before and after reading educational materials.RESULTS: A total of 225 (47.67%) patients with Crohn's disease, 244 (51.69%) with ulcerative colitis and 3 (0.64%) with indeterminate colitis were enrolled. Common concerns were adverse events from vaccination (20.34%), and higher risks of developing severe COVID-19 (19.28%) and COVID-19 infection (16.31%) than the general population. Medications deemed by the patients to increase the risk of COVID-19 were immunomodulators (16.10%), anti-tumor necrosis factor-α antagonists (9.96%), and corticosteroids (9.32%). Thirty-five (7.42%) patients self-discontinued IBD medication, of whom 12 (34.28%) had worse symptoms. Older age (>50 years) (OR 1.10, 95% CI 1.01-1.19, p = 0.03), IBD-related complications (OR 1.16, 95% CI 1.04-1.28, p = 0.01), education status below senior high school (OR 1.22, 95% CI 1.08-1.37, p = 0.001), and residing in north-central Taiwan (OR 1.21, 95% CI 1.10-1.34, p < 0.001) were associated with more anxiety. None of the enrolled patients contracted COVID-19. The anxiety VAS score (mean ± SD) improved after reading the educational materials (3.84 ± 2.33 vs. 2.81 ± 1.96, p < 0.001).CONCLUSION: The medical behavior of IBD patients was influenced by the COVID-19 pandemic, and their anxiety could be mitigated after education.

AB - BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic had a great impact on healthcare system and patients. This study aimed to evaluate the effect of the COVID-19 pandemic on the perceptions of patients with inflammatory bowel disease (IBD).METHODS: This prospective multicenter study was conducted between July 2021 and December 2021. Patients with IBD answered a structured questionnaire, and their degree of anxiety was assessed using a visual analogue scale (VAS) before and after reading educational materials.RESULTS: A total of 225 (47.67%) patients with Crohn's disease, 244 (51.69%) with ulcerative colitis and 3 (0.64%) with indeterminate colitis were enrolled. Common concerns were adverse events from vaccination (20.34%), and higher risks of developing severe COVID-19 (19.28%) and COVID-19 infection (16.31%) than the general population. Medications deemed by the patients to increase the risk of COVID-19 were immunomodulators (16.10%), anti-tumor necrosis factor-α antagonists (9.96%), and corticosteroids (9.32%). Thirty-five (7.42%) patients self-discontinued IBD medication, of whom 12 (34.28%) had worse symptoms. Older age (>50 years) (OR 1.10, 95% CI 1.01-1.19, p = 0.03), IBD-related complications (OR 1.16, 95% CI 1.04-1.28, p = 0.01), education status below senior high school (OR 1.22, 95% CI 1.08-1.37, p = 0.001), and residing in north-central Taiwan (OR 1.21, 95% CI 1.10-1.34, p < 0.001) were associated with more anxiety. None of the enrolled patients contracted COVID-19. The anxiety VAS score (mean ± SD) improved after reading the educational materials (3.84 ± 2.33 vs. 2.81 ± 1.96, p < 0.001).CONCLUSION: The medical behavior of IBD patients was influenced by the COVID-19 pandemic, and their anxiety could be mitigated after education.

KW - COVID-19

KW - Inflammatory bowel disease

KW - Patient education

KW - SARS-CoV-2

KW - Inflammatory Bowel Diseases/complications

KW - COVID-19/epidemiology

KW - Pandemics

KW - Prospective Studies

KW - Humans

KW - Taiwan/epidemiology

UR - http://www.scopus.com/inward/record.url?scp=85151572816&partnerID=8YFLogxK

U2 - 10.1016/j.jfma.2023.03.017

DO - 10.1016/j.jfma.2023.03.017

M3 - 文章

C2 - 37019722

AN - SCOPUS:85151572816

SN - 0929-6646

VL - 122

SP - 1042

EP - 1049

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

IS - 10

ER -

Impact of the COVID-19 pandemic on inflammatory bowel disease care in Taiwan: A multicenter study

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this